Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

6.890 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,306
Open 6.890
Bid (Size) 6.900 (3)
Ask (Size) 6.950 (1)
Prev. Close 6.890
Today's Range 6.890 - 6.890
52wk Range 2.090 - 14.84
Shares Outstanding 70,895,286
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one. 
Via InvestorPlace
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate. 
Via The Motley Fool

Performance

YTD
-34.51%
-34.51%
1 Month
-21.17%
-21.17%
3 Month
-36.14%
-36.14%
6 Month
+195.71%
+195.71%
1 Year
+15.41%
+15.41%

More News

Read More
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Via MarketBeat
Exposures Product Safety
How Is The Market Feeling About Altimmune?
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Via Benzinga
ALT Stock Earnings: Altimmune Beats EPS for Q4 2023
Via InvestorPlace
Altimmune's Earnings Outlook
Via Benzinga
(ALT) - Analyzing Altimmune's Short Interest
Via Benzinga
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
Via Benzinga
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Here's How Much $100 Invested In Altimmune 5 Years Ago Would Be Worth Today
Via Benzinga
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
Via Investor's Business Daily
7 Stocks That Will Drive the Weight Loss Drugs Market
Via MarketBeat
Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 27, 2024
Via Benzinga
Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
Via Benzinga
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Via The Motley Fool
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Via NewMediaWire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Via TheNewswire.com
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Via NewMediaWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Via TheNewswire.com
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
ALT LOSS ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.